Zai Lab Limited
ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infectionsā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$20.41
Price+0.35%
$0.07
1Y
Price
Market Cap
$2.259b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-37.7%
EBITDA Margin-39.5%
Net Profit Margin-20.1%
Free Cash Flow Margin-37.7%
EBITDA Margin-39.5%
Net Profit Margin-20.1%
Free Cash Flow MarginRevenue
$460.156m
+15.3%
1y CAGR+29.7%
3y CAGR+34.5%
5y CAGREarnings
-$175.537m
+31.7%
1y CAGR+26.5%
3y CAGR+29.1%
5y CAGREPS
-$1.60
+38.1%
1y CAGR+52.0%
3y CAGR+48.7%
5y CAGRBook Value
$715.500m
$1.172b
Assets$456.884m
Liabilities$224.259m
DebtDebt to Assets
19.1%
-1.4x
Debt to EBITDAFree Cash Flow
-$158.890m
+42.5%
1y CAGR+18.7%
3y CAGR+21.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company